Scarica l'app Stockscreener
1.64
6.82%
-0.12
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics chief legal officer sells $585 in stock - Investing.com
Form 4 Acrivon Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
Mary Miller Executes Automatic Sale of 294 Shares at $1.99 for RSU Tax Withholding at Acrivon Therapeutics - Kalkine Media
Automatic tax withholding triggers a 294-share sale by Acrivon Therapeutics (ACRV) legal chief - Stock Titan
Form 4 Acrivon Therapeutics Inc For: 7 October By Investing.com - Investing.com Nigeria
Acrivon Therapeutics chief legal officer sells $585 in stock By Investing.com - Investing.com UK
ACRV 8-K & SEC Filings - Yahoo Finance Australia
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com Canada
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com India
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com UK
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - The Manila Times
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Acrivon Therapeutics files Form 3 for Chief Business Officer Michaela Levin - Bitget
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Nigeria
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com India
Acrivon Therapeutics Names Michaela Levin Chief Business Officer - citybiz
acrivon appoints michaela levin as chief business officer - investing.com
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Canada
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com UK
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - GlobeNewswire
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - The Manila Times
ACRV Q2 2026 Earnings: Narrower-Than-Expected Loss in a Pre-Revenue QuarterProfit Margin Analysis - vinanet.vn
Acrivon (NASDAQ: ACRV) CEO sells 14K shares to cover RSU taxes - Stock Titan
Acrivon (NASDAQ: ACRV) CEO may sell stock from vested RSUs - Stock Titan
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Acrivon Therapeutics (ACRV) CLO sells 185 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
Acrivon (NASDAQ: ACRV) chiefs sell shares to cover RSU taxes - Stock Titan
Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the DayFull Year Guidance - vinanet.vn
ACRV Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 5.9%Capex Guidance - vinanet.vn
Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat
ACRV Q1 2026 Earnings: Loss Narrower Than Expected, Stock Advances 5.41%Forward EPS Estimate - Vinanet
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat
Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks
Acrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M - scanx.trade
Acrivon Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Imbalance Zone - Vinanet
Acrivon Therapeutics Q2 net loss narrows as costs decline - TradingView
BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 Million - TradingView
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewswire
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Island Reversal - dars.gov.et
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):